{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:29:51Z","timestamp":1781112591151,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T00:00:00Z","timestamp":1492560000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Ministry of Science and Technology of the People's Republic of China (CN)","award":["No. 2012ZX09401008"],"award-info":[{"award-number":["No. 2012ZX09401008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00592-017-0992-z","type":"journal-article","created":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T03:53:06Z","timestamp":1492573986000},"page":"685-693","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of GW002, a novel recombinant human glucagon-like peptide-1 (GLP-1) analog fusion protein, on CHO recombinant cells and BKS-db mice"],"prefix":"10.1007","volume":"54","author":[{"given":"Wan-Wan","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-An","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Er-Bing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shou-Sheng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,19]]},"reference":[{"key":"992_CR1","unstructured":"World Health Organization (2016) Global report on diabetes. ISBN 978 92 4 156525 7"},{"key":"992_CR2","doi-asserted-by":"publisher","DOI":"10.1289\/image.ehp.v119.i03","author":"S Edition","year":"2015","unstructured":"Edition S (2015) Diabetes. Int Diabetes Fed. doi:\n                        10.1289\/image.ehp.v119.i03","journal-title":"Int Diabetes Fed"},{"key":"992_CR3","doi-asserted-by":"publisher","first-page":"646","DOI":"10.2471\/BLT.09.070565","volume":"87","author":"WHO","year":"2009","unstructured":"WHO (2009) Global health risks: mortality and burden of disease attributable to selected major risks. Bull World Health Organ 87:646. doi:\n                        10.2471\/BLT.09.070565","journal-title":"Bull World Health Organ"},{"key":"992_CR4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1586\/17512433.2016.1121808","volume":"9","author":"L \u00d8stergaard","year":"2016","unstructured":"\u00d8stergaard L, Frandsen CS, Madsbad S (2016) Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review. Expert Rev Clin Pharmacol 9:241\u2013265. doi:\n                        10.1586\/17512433.2016.1121808","journal-title":"Expert Rev Clin Pharmacol"},{"key":"992_CR5","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1021\/bi051833a","volume":"45","author":"A Wittelsberger","year":"2006","unstructured":"Wittelsberger A, Corich M, Thomas BE et al (2006) The mid-region of parathyroid hormone (1\u201334) serves as a functional docking domain in receptor activation. Biochemistry 45:2027\u20132034. doi:\n                        10.1021\/bi051833a","journal-title":"Biochemistry"},{"key":"992_CR6","doi-asserted-by":"publisher","first-page":"48300","DOI":"10.1074\/jbc.M309166200","volume":"278","author":"M Dong","year":"2003","unstructured":"Dong M, Li Z, Zang M et al (2003) Spatial approximation between two residues in the mid-region of secretin and the amino terminus of its receptor. Incorporation of seven sets of such constraints into a three-dimensional model of the agonist-bound secretin receptor. J Biol Chem 278:48300\u201348312. doi:\n                        10.1074\/jbc.M309166200","journal-title":"J Biol Chem"},{"key":"992_CR7","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1124\/pr.108.000604.470","volume":"60","author":"A P\u00e9rez G\u00f3mez","year":"2009","unstructured":"P\u00e9rez G\u00f3mez A (2009) Micro tr\u00e1fico de hero\u00edna, un tercer estudio realizado en Medell\u00edn y Bogot\u00e1 en el 2009. Adicciones Rev Socidrogalcohol 60:470\u2013512. doi:\n                        10.1124\/pr.108.000604.470","journal-title":"Adicciones Rev Socidrogalcohol"},{"key":"992_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejps.2006.01.003","volume":"28","author":"DK Arulmozhi","year":"2006","unstructured":"Arulmozhi DK, Portha B (2006) GLP-1 based therapy for type 2 diabetes. Eur J Pharm Sci 28:96\u2013108. doi:\n                        10.1016\/j.ejps.2006.01.003","journal-title":"Eur J Pharm Sci"},{"key":"992_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.regpep.2004.06.018","volume":"128","author":"J Schirra","year":"2005","unstructured":"Schirra J, G\u00f6ke B (2005) The physiological role of GLP-1 in human: incretin, ileal brake or more? Regul Pept 128:109\u2013115. doi:\n                        10.1016\/j.regpep.2004.06.018","journal-title":"Regul Pept"},{"key":"992_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00441-014-1959-9","volume":"358","author":"M Lotfy","year":"2014","unstructured":"Lotfy M, Singh J, Rashed H et al (2014) The effect of glucagon-like peptide-1 in the management of diabetes mellitus: cellular and molecular mechanisms. Cell Tissue Res 358:343\u2013358. doi:\n                        10.1007\/s00441-014-1959-9","journal-title":"Cell Tissue Res"},{"key":"992_CR11","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/phar.1507","volume":"34","author":"JM Trujillo","year":"2014","unstructured":"Trujillo JM, Nuffer W (2014) GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Pharmacotherapy 34:1174\u20131186. doi:\n                        10.1002\/phar.1507","journal-title":"Pharmacotherapy"},{"key":"992_CR12","doi-asserted-by":"publisher","first-page":"CD006423","DOI":"10.1002\/14651858.CD006423.pub2","volume":"71","author":"DS Shyangdan","year":"2011","unstructured":"Shyangdan DS, Royle P, Clar C et al (2011) Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 71:CD006423. doi:\n                        10.1002\/14651858.CD006423.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"992_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1185\/030079908X253870","volume":"24","author":"K Dc","year":"2008","unstructured":"Dc K, Jb B, Ll N et al (2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3\u00a0years. Curr Med Res Opin 24:275\u2013286. doi:\n                        10.1185\/030079908X253870","journal-title":"Curr Med Res Opin"},{"key":"992_CR14","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/ajh.2009.245","volume":"23","author":"T Okerson","year":"2010","unstructured":"Okerson T, Yan P, Stonehouse A, Brodows R (2010) Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens 23:334\u2013339. doi:\n                        10.1038\/ajh.2009.245","journal-title":"Am J Hypertens"},{"key":"992_CR15","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1056\/NEJMc1611289","volume":"375","author":"Cohen P Scott","year":"2016","unstructured":"Scott Cohen P, Cherylyn Beckey PD (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:1797\u20131799. doi:\n                        10.1056\/NEJMc1611289","journal-title":"N Engl J Med"},{"key":"992_CR16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1590\/S0100-879X2010007500030","volume":"43","author":"CMM Marques","year":"2010","unstructured":"Marques CMM, Motta VF, Torres TS et al (2010) Beneficial effects of exercise training (treadmill) on insulin resistance and nonalcoholic fatty liver disease in high-fat fed C57BL\/6 mice. Braz J Med Biol Res 43:467\u2013475","journal-title":"Braz J Med Biol Res"},{"key":"992_CR17","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1210\/er.2007-0031","volume":"29","author":"M Salehi","year":"2008","unstructured":"Salehi M, Aulinger BA, D\u2019Alessio DA (2008) Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. Endocr Rev 29:367\u2013379. doi:\n                        10.1210\/er.2007-0031","journal-title":"Endocr Rev"},{"key":"992_CR18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.cmet.2011.02.002","volume":"13","author":"WJ Song","year":"2011","unstructured":"Song WJ, Seshadri M, Ashraf U et al (2011) Snapin mediates incretin action and augments glucose-dependent insulin secretion. Cell Metab 13:308\u2013319. doi:\n                        10.1016\/j.cmet.2011.02.002","journal-title":"Cell Metab"},{"key":"992_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1385\/ENDO:27:1:001","volume":"27","author":"ME Doyle","year":"2005","unstructured":"Doyle ME, McConville P, Theodorakis MJ et al (2005) In vivo biological activity of exendin (1\u201330). Endocrine 27:1\u20139. doi:\n                        10.1385\/ENDO:27:1:001","journal-title":"Endocrine"},{"key":"992_CR20","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/817839","author":"S Hou","year":"2015","unstructured":"Hou S, Li C, Huan Y et al (2015) Effects of E2HSA, a long-acting glucagon like peptide-1 receptor agonist, on glycemic control and beta cell function in spontaneous diabetic db\/db mice. J Diabetes Res. doi:\n                        10.1155\/2015\/817839","journal-title":"J Diabetes Res"},{"key":"992_CR21","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006","author":"JJ Holst","year":"2007","unstructured":"Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev. doi:\n                        10.1152\/physrev.00034.2006","journal-title":"Physiol Rev"},{"key":"992_CR22","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1271\/bbb.80742","volume":"73","author":"Z Gao","year":"2009","unstructured":"Gao Z, Bai G, Chen J et al (2009) Development, characterization, and evaluation of a fusion protein of a novel glucagon-like peptide-1 (GLP-1) analog and human serum albumin in Pichia pastoris. Biosci Biotechnol Biochem 73:688\u2013694. doi:\n                        10.1271\/bbb.80742","journal-title":"Biosci Biotechnol Biochem"},{"key":"992_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1152\/ajpgi.00274.2011","volume":"302","author":"JE Mells","year":"2012","unstructured":"Mells JE, Fu PP, Sharma S et al (2012) Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL\/6\u00a0J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol 302:225\u2013235. doi:\n                        10.1152\/ajpgi.00274.2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"992_CR24","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1007\/s11434-013-5915-y","volume":"58","author":"C Ying","year":"2013","unstructured":"Ying C, Congfeng W, Xin ZOU (2013) A new long-acting GLP-1 derivative KTP ameliorates hyperglycemia and dyslipidemia and improves pancreas and fatty liver in db\/db mice. Chin Sci Bull 58:2447\u20132453. doi:\n                        10.1007\/s11434-013-5915-y","journal-title":"Chin Sci Bull"},{"key":"992_CR25","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.2337\/db09-1564","volume":"59","author":"BP Cummings","year":"2010","unstructured":"Cummings BP, Stanhope KL, Graham JL et al (2010) Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats. Diabetes 59:2653\u20132661. doi:\n                        10.2337\/db09-1564","journal-title":"Diabetes"},{"issue":"11","key":"992_CR26","doi-asserted-by":"publisher","first-page":"e49152","DOI":"10.1371\/journal.pone.0049152","volume":"7","author":"D Elst","year":"2012","unstructured":"Elst D, Picha K, Parlevliet ET et al (2012) GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE* 3-Leiden mice. PLoS ONE 7(11):e49152. doi:\n                        10.1371\/journal.pone.0049152","journal-title":"PLoS ONE"},{"key":"992_CR27","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1152\/ajpgi.00303.2004","volume":"288","author":"X Qin","year":"2005","unstructured":"Qin X, Shen H, Liu M et al (2005) GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol 288:943\u2013949. doi:\n                        10.1152\/ajpgi.00303.2004","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"992_CR28","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1053\/j.gastro.2008.01.017","volume":"134","author":"LL Baggio","year":"2008","unstructured":"Baggio LL, Huang Q, Cao X, Drucker DJ (2008) An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology 134:1137\u20131147. doi:\n                        10.1053\/j.gastro.2008.01.017","journal-title":"Gastroenterology"},{"key":"992_CR29","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.2337\/diabetes.50.11.2530","volume":"50","author":"PJ Larsen","year":"2001","unstructured":"Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M (2001) Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 50:2530\u20132539. doi:\n                        10.2337\/diabetes.50.11.2530","journal-title":"Diabetes"},{"key":"992_CR30","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2337\/diabetes.52.3.751","volume":"52","author":"P Conjugate","year":"2003","unstructured":"Conjugate P, Kim J, Baggio LL et al (2003) Development and characterization of a glucagon-like peptide 1-albumin conjugate. Diabetes 52:751\u2013759. doi:\n                        10.2337\/diabetes.52.3.751","journal-title":"Diabetes"},{"key":"992_CR31","doi-asserted-by":"publisher","first-page":"E745","DOI":"10.1152\/ajpendo.00030.2002","volume":"283","author":"B Rolin","year":"2002","unstructured":"Rolin B, Larsen MO, Gotfredsen CF et al (2002) The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 283:E745\u2013E752. doi:\n                        10.1152\/ajpendo.00030.2002","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"992_CR32","unstructured":"European Medicines Agency (2014) Assessment report. 44:1\u2013107"},{"key":"992_CR33","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","volume":"48","author":"G Shankar","year":"2008","unstructured":"Shankar G, Devanarayan V, Amaravadi L et al (2008) Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 48:1267\u20131281. doi:\n                        10.1016\/j.jpba.2008.09.020","journal-title":"J Pharm Biomed Anal"},{"key":"992_CR34","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1463-1326.2008.00992.x","volume":"11","author":"MA Bush","year":"2009","unstructured":"Bush MA, Matthews JE, De Boever EH et al (2009) Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab 11:498\u2013505. doi:\n                        10.1111\/j.1463-1326.2008.00992.x","journal-title":"Diabetes Obes Metab"},{"key":"992_CR35","doi-asserted-by":"publisher","first-page":"4810","DOI":"10.1210\/jc.2008-1518","volume":"93","author":"JE Matthews","year":"2008","unstructured":"Matthews JE, Stewart MW, De Boever EH et al (2008) Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 93:4810\u20134817. doi:\n                        10.1210\/jc.2008-1518","journal-title":"J Clin Endocrinol Metab"},{"key":"992_CR36","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.drudis.2011.01.011","volume":"16","author":"MDFS Barbosa","year":"2011","unstructured":"Barbosa MDFS (2011) Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters. Drug Discov Today 16:345\u2013353. doi:\n                        10.1016\/j.drudis.2011.01.011","journal-title":"Drug Discov Today"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00592-017-0992-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-017-0992-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-017-0992-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,14]],"date-time":"2017-06-14T04:04:20Z","timestamp":1497413060000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00592-017-0992-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,19]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["992"],"URL":"https:\/\/doi.org\/10.1007\/s00592-017-0992-z","relation":{},"ISSN":["0940-5429","1432-5233"],"issn-type":[{"value":"0940-5429","type":"print"},{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,19]]}}}